MCID: BLL006
MIFTS: 64

Bullous Pemphigoid

Categories: Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Bullous Pemphigoid

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid 12 72 49 55 14 69
Senile Dermatitis Herpetiformis 49 69
Benign Pemphigus 49 69
Pemphigoid 49 36
Pemphigoid, Bullous 41
Pemphigoid Bullous 51
Old Age Pemphigus 49
Parapemphigus 49

Characteristics:

Orphanet epidemiological data:

55
bullous pemphigoid
Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8506
ICD10 32 L12 L12.0 L12.9
ICD9CM 34 694.5
MeSH 41 D010391
Orphanet 55 ORPHA703
MESH via Orphanet 42 D010391
UMLS via Orphanet 70 C0030805
ICD10 via Orphanet 33 L12.0
KEGG 36 H01650

Summaries for Bullous Pemphigoid

NIH Rare Diseases : 49 Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. In some people, the mouth or genitals are also affected. The blisters may break open and form ulcers or open sores. Bullous pemphigoid usually occurs in older persons and is rare in young people. Symptoms may come and go. In most patients, the condition goes away after several years. Bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake. Treatment may include corticosteroids taken by mouth or applied to the skin. Medicines that suppress the immune system may also be prescribed. For some, antibiotics in the tetracycline family are useful. Last updated: 8/10/2016

MalaCards based summary : Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to lichen planus pemphigoides and dermatitis herpetiformis, and has symptoms including diabetes mellitus, eczema and urticaria. An important gene associated with Bullous Pemphigoid is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Clobetasol and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are digestive/alimentary and immune system

Disease Ontology : 12 An autoimmune disease of skin and connective tissue characterized by large blisters.

Wikipedia : 72 Bullous pemphigoid is an acute or chronic autoimmune skin disease, involving the formation of blisters,... more...

Related Diseases for Bullous Pemphigoid

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 33.0 COL17A1 DST ITGB4
2 dermatitis herpetiformis 30.9 CCL11 CD79A HLA-DQB1
3 lichen planus 30.7 COL17A1 DSG3 DST
4 pemphigoid gestationis 30.4 CCL11 COL17A1 DST HLA-DRB1 IL5
5 epidermolysis bullosa acquisita 30.3 CD79A COL17A1 DST ITGB4 LAMA3
6 herpetiform pemphigus 30.3 DSG1 DSG3 DST
7 epidermolysis bullosa simplex 30.3 COL17A1 DST PLEC
8 chronic eosinophilic pneumonia 30.3 CCL11 IL5 RNASE3
9 linear iga disease 30.3 CD79A COL17A1 DST ITGB4
10 conjunctivitis 30.2 CCL11 IL5 RNASE3
11 gastroenteritis 30.2 CCL11 IL5 RNASE3
12 herpes gestationis 30.2 CD79A COL17A1 DST PLEC RNASE3
13 esophagitis 30.1 CCL11 DSG1 IL5
14 dermatitis 30.0 CCL11 CCL17 DSG1 IL5 RNASE3
15 cicatricial pemphigoid 30.0 CD79A COL17A1 DST ITGB4 LAMA3 LAMC2
16 erythema multiforme 29.8 CCL17 CD79A DSP
17 pemphigus foliaceus 29.8 DSG1 DSG3 DST EVPL HLA-DRB1 PPL
18 autoimmune disease 29.7 CD79A COL17A1 DSG1 HLA-DQB1 HLA-DRB1 IL5
19 allergic hypersensitivity disease 29.7 CCL11 CCL17 IL5 RNASE3
20 pemphigus vulgaris 29.6 DSG1 DSG3 DSP DST EVPL HLA-DRB1
21 churg-strauss syndrome 29.6 CCL17 IL5 RNASE3
22 pemphigus 29.5 CD79A COL17A1 DSG1 DSG3 DSP DST
23 ocular cicatricial pemphigoid 29.5 CD79A HLA-DQB1 HLA-DRB1 ITGA6 ITGB4 RNASE3
24 eosinophilic pneumonia 29.4 CCL11 CCL17 IL5 RNASE3
25 hypereosinophilic syndrome 29.4 CCL11 CCL17 IL5 RNASE3
26 junctional epidermolysis bullosa 29.3 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
27 dermatitis, atopic 29.3 CCL11 CCL17 IL5 RNASE3
28 epidermolysis bullosa 29.3 COL17A1 DSP DST ITGA6 ITGB4 LAMA3
29 epidermolysis bullosa, junctional, non-herlitz type 28.6 CD79A COL17A1 DST ITGA6 ITGB4 LAMA3
30 paraneoplastic pemphigus 28.5 COL17A1 DSG1 DSG3 DSP DST EVPL
31 skin disease 28.3 CCL17 CD79A COL17A1 DSG1 DSG3 DST
32 subcorneal pustular dermatosis 27.8 CCL17 CD79A COL17A1 DSG1 DSG3 DST
33 bullous skin disease 27.3 CD79A COL17A1 DSG1 DSG3 DSP DST
34 autoimmune disease, multisystem, infantile-onset, 2 11.1
35 limbic encephalitis with lgi1 antibodies 10.5 HLA-DQB1 HLA-DRB1
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
37 loeffler endocarditis 10.5 IL5 RNASE3
38 neurotic excoriation 10.5 COL17A1 DST
39 pemphigus erythematosus 10.5 DSG3 DSP
40 eosinophilic gastroenteritis 10.5 CCL11 IL5 RNASE3
41 metal allergy 10.5 HLA-DQB1 HLA-DRB1
42 chronic conjunctivitis 10.4 CCL11 IL5 RNASE3
43 kimura disease 10.4 CCL11 IL5 RNASE3
44 pustulosis of palm and sole 10.4
45 psoriasis 10.4
46 focal epithelial hyperplasia 10.4 HLA-DQB1 HLA-DRB1
47 vernal keratoconjunctivitis 10.4 CCL11 IL5 RNASE3
48 latex allergy 10.4 HLA-DQB1 IL5 RNASE3
49 erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper-ige 10.4 DSG1 DSP
50 beryllium disease 10.4 HLA-DQB1 HLA-DRB1

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Pemphigus Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:



Diseases related to Bullous Pemphigoid

Symptoms & Phenotypes for Bullous Pemphigoid

Human phenotypes related to Bullous Pemphigoid:

55 31 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 55 31 hallmark (90%) Very frequent (99-80%) HP:0000819
2 eczema 55 31 hallmark (90%) Very frequent (99-80%) HP:0000964
3 urticaria 55 31 hallmark (90%) Very frequent (99-80%) HP:0001025
4 weight loss 55 31 hallmark (90%) Very frequent (99-80%) HP:0001824
5 recurrent infections 55 31 hallmark (90%) Very frequent (99-80%) HP:0002719
6 autoimmunity 55 31 hallmark (90%) Very frequent (99-80%) HP:0002960
7 abnormal blistering of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0008066
8 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
9 macule 55 31 hallmark (90%) Very frequent (99-80%) HP:0012733
10 psoriasis 55 Frequent (79-30%)
11 psoriasiform dermatitis 31 frequent (33%) HP:0003765

MGI Mouse Phenotypes related to Bullous Pemphigoid:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.91 ITGA6 ITGB4 LAMA3 DSG3 LAMB3 DSP
2 immune system MP:0005387 9.9 ITGA6 ITGB4 CCL11 CCL17 CD79A LAMA3
3 craniofacial MP:0005382 9.87 ITGA6 ITGB4 LAMA3 DSG3 LAMB3 DSP
4 integument MP:0010771 9.65 ITGA6 ITGB4 LAMA3 DSG1 DSG3 LAMB3
5 respiratory system MP:0005388 9.28 ITGA6 ITGB4 CCL11 LAMA3 DSG3 LAMB3

Drugs & Therapeutics for Bullous Pemphigoid

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2 25122-41-2, 25122-46-7 5311051 32798
2
Omalizumab Approved, Investigational Phase 4 242138-07-4
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4 glucocorticoids Phase 4,Phase 3,Phase 2
5 Hormone Antagonists Phase 4,Phase 3,Phase 2
6 Hormones Phase 4,Phase 3,Phase 2
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
9 Respiratory System Agents Phase 4
10 Anti-Allergic Agents Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Immunoglobulin E Phase 4
13 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Hormonal Phase 4
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
18
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
19
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
20
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
21
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
23 Folic Acid Antagonists Phase 3
24 Nucleic Acid Synthesis Inhibitors Phase 3
25 Dermatologic Agents Phase 3,Phase 1,Phase 2
26 Vitamin B Complex Phase 3,Phase 1,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2
28 Antimetabolites Phase 3,Phase 2,Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1
31 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1
32 gamma-Globulins Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2
34 Anti-Infective Agents Phase 3,Phase 2
35 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 3,Phase 2
37 Antitubercular Agents Phase 3,Phase 2
38 Alkylating Agents Phase 3
39 Folate Nutraceutical Phase 3,Phase 1,Phase 2
40 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
41
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
42
Azathioprine Approved Phase 2 446-86-6 2265
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
45
Infliximab Approved Phase 1, Phase 2 170277-31-3
46
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
47 Gastrointestinal Agents Phase 1, Phase 2
48 Prednisolone acetate Phase 2
49 Methylprednisolone acetate Phase 2
50 Methylprednisolone Hemisuccinate Phase 2

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
2 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Phase 4 Dermoval
3 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
4 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
5 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
6 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
7 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
8 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
10 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
11 Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
12 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
13 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
14 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
15 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
16 Ixekizumab in the Treatment of Bullous Pemphigoid Recruiting NCT03099538 Phase 2 Ixekizumab
17 A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Recruiting NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
18 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Recruiting NCT02226146 Phase 2
19 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
20 Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
21 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
22 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
23 The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
24 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
25 Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders Recruiting NCT02502903 Phase 1 TNT009
26 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
27 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
28 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Unknown status NCT01559155
29 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
30 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675
31 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
32 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
33 Register of Autoimmune Bullous Dermatoses Completed NCT02899923
34 Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Completed NCT00116090
35 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
36 Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid Recruiting NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
37 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Recruiting NCT02874079
38 Autoimmune Blistering Diseases Study Recruiting NCT02753777
39 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313
40 Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients Recruiting NCT03129308
41 Pruritus and Pemphigoid in Nursing Home Patients Active, not recruiting NCT02823067
42 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
43 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Enrolling by invitation NCT00357071
44 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Not yet recruiting NCT03272958
45 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Not yet recruiting NCT02872584 Prednisone
46 Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 Withdrawn NCT03421548

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: pemphigoid, bullous

Genetic Tests for Bullous Pemphigoid

Anatomical Context for Bullous Pemphigoid

MalaCards organs/tissues related to Bullous Pemphigoid:

38
Skin, Eye, Testes, T Cells, Neutrophil, B Cells, Breast

Publications for Bullous Pemphigoid

Articles related to Bullous Pemphigoid:

(show top 50) (show all 1001)
# Title Authors Year
1
Bulla formation at the tuberculin skin test site in a patient with bullous pemphigoid: Koebnerization or severe delayed-type hypersensitivity? ( 29376506 )
2018
2
Detection of I+-defensin in blister fluids as potential biomarkers for bullous pemphigoid patients by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. ( 29407691 )
2018
3
Unilateral, localized bullous pemphigoid in a patient with chronic venous stasis. ( 29387773 )
2018
4
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. ( 29446164 )
2018
5
Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. ( 29389067 )
2018
6
Intravenous immunoglobulin reduces pathogenic autoantibodies, serum IL-6 levels and disease severity in experimental bullous pemphigoid models. ( 29391250 )
2018
7
Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment. ( 29400293 )
2018
8
HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 Alleles Associated to Bullous Pemphigoid in Brazilian Population. ( 29386826 )
2018
9
Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid. ( 29374651 )
2018
10
Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. ( 29386827 )
2018
11
Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement. ( 29380425 )
2018
12
Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding sub-clinical lesions. ( 29341355 )
2018
13
Hemorrhagic vesiculobullous eruption on the palms and the soles as presentation of dyshidrosiform bullous pemphigoid. ( 29387751 )
2018
14
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
15
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. ( 29411416 )
2018
16
BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. ( 29423547 )
2018
17
The skin-kidney connection: bullous pemphigoid associated with acute allograft rejection and membranous nephropathy. ( 29445491 )
2018
18
Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study. ( 29427585 )
2018
19
Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid. ( 29441558 )
2018
20
A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. ( 29378676 )
2018
21
Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. ( 28852833 )
2017
22
Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient. ( 28487841 )
2017
23
An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. ( 28494097 )
2017
24
Langerhans cells are predominant high affinity immunoglobulin E receptor bearing cells in the epidermis of bullous pemphigoid skin. ( 27839901 )
2017
25
Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid. ( 28465041 )
2017
26
Extensive milia formation in a young woman with bullous pemphigoid. ( 28440230 )
2017
27
Immunoglobulin E Autoantibodies in Bullous Pemphigoid Detected by Immunoglobulin E Enzyme-Linked Immunosorbent Assays. ( 27829077 )
2017
28
TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid. ( 28351660 )
2017
29
Glucocorticoids: the mode of action in bullous pemphigoid. ( 28771827 )
2017
30
Bullous Pemphigoid associated with Dipeptidyl Peptidase-4 Inhibitors: A Report of Five Cases. ( 28520234 )
2017
31
Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE. ( 28823642 )
2017
32
Image Gallery: Juvenile cutaneous chronic graft-versus-host disease presenting as bullous pemphigoid. ( 28940263 )
2017
33
A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. ( 27876358 )
2017
34
Bullous Pemphigoid Successfully Treated With a Combination Therapy of Plasmapheresis Followed by Intravenous High Dose Immunoglobulin. ( 28378368 )
2017
35
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
36
Bullous pemphigoid with IgG autoantibodies to the I+3 subunit of laminin 332 associated with psoriasis vulgaris. ( 28468743 )
2017
37
Case of bullous pemphigoid accompanied by collagenous gastroenteritis. ( 28862318 )
2017
38
Eosinophils mediate tissue injury in autoimmune skin disease bullous pemphigoid. ( 29246800 )
2017
39
Complement-independent blistering mechanisms in bullous pemphigoid. ( 28418613 )
2017
40
Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. ( 27829102 )
2017
41
Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin. ( 28508388 )
2017
42
Distinguishing Epidermolysis Bullosa Acquisita From Bullous Pemphigoid Without Direct Immunofluorescence. ( 28719980 )
2017
43
Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis. ( 29203970 )
2017
44
A Case of Wolf's Isotopic Response Presenting as Bullous Pemphigoid. ( 28761305 )
2017
45
Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. ( 28500685 )
2017
46
The Role of Intereukin-31 in Pathogenesis of Itch and Its Intensity in a Course of Bullous Pemphigoid and Dermatitis Herpetiformis. ( 28808661 )
2017
47
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. ( 28413387 )
2017
48
Bullous pemphigoid associated with silicosis. ( 28622458 )
2017
49
Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome. ( 28887823 )
2017
50
Survey of bullous pemphigoid in an Italian University hospital: clinical-epidemiological characteristics and follow-up. ( 28079339 )
2017

Variations for Bullous Pemphigoid

Expression for Bullous Pemphigoid

Search GEO for disease gene expression data for Bullous Pemphigoid.

Pathways for Bullous Pemphigoid

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 CCL11 CCL17 COL17A1 DSP IL5 ITGA6
2
Show member pathways
13.26 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
3
Show member pathways
12.96 CD79A COL17A1 ITGA6 ITGB4 LAMA3 LAMB3
4
Show member pathways
12.8 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5
Show member pathways
12.76 CCL11 HLA-DQB1 HLA-DRB1 IL5 RNASE3
6 12.75 IL5 ITGA6 LAMA3 LAMB3 LAMC2
7
Show member pathways
12.71 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
8
Show member pathways
12.69 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
9
Show member pathways
12.42 DSG1 DSG3 DSP EVPL PPL
10
Show member pathways
12.41 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
11
Show member pathways
12.22 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
12
Show member pathways
12.18 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
13
Show member pathways
12.15 HLA-DQB1 HLA-DRB1 ITGA6 LAMA3 LAMB3 LAMC2
14
Show member pathways
12.03 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
15
Show member pathways
11.96 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
16 11.94 DSP ITGA6 ITGB4 PLEC
17
Show member pathways
11.91 DSG1 DSG3 DSP PLEC
18
Show member pathways
11.86 DSP DST EVPL PLEC PPL
19 11.8 HLA-DQB1 HLA-DRB1 IL5 ITGA6
20 11.79 LAMA3 LAMB3 LAMC2
21 11.76 ITGA6 LAMA3 LAMB3 LAMC2
22 11.59 CCL11 CCL17 IL5
23 11.58 CCL11 DSP IL5
24 11.56 LAMA3 LAMB3 LAMC2
25
Show member pathways
11.55 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
26 11.52 DSG1 HLA-DQB1 HLA-DRB1
27 11.42 CCL11 CCL17 IL5
28 11.2 COL17A1 ITGA6 ITGB4
29 10.18 CCL11 CCL17 COL17A1 IL5 ITGA6 ITGB4

GO Terms for Bullous Pemphigoid

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSG1 DSG3 DSP DST EVPL
2 cornified envelope GO:0001533 9.65 DSG1 DSG3 DSP EVPL PPL
3 basement membrane GO:0005604 9.63 COL17A1 DST ITGA6 LAMA3 LAMB3 LAMC2
4 MHC class II protein complex GO:0042613 9.43 HLA-DQB1 HLA-DRB1
5 laminin-5 complex GO:0005610 9.37 LAMA3 LAMB3
6 desmosome GO:0030057 9.35 DSG1 DSG3 DSP EVPL PPL
7 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC
8 extracellular exosome GO:0070062 10.14 DSG1 DSG3 DSP DST EVPL HLA-DRB1

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 CCL11 CCL17 HLA-DQB1 HLA-DRB1 IL5
2 cell adhesion GO:0007155 9.81 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 extracellular matrix organization GO:0030198 9.77 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
4 cell-matrix adhesion GO:0007160 9.73 COL17A1 ITGA6 ITGB4
5 integrin-mediated signaling pathway GO:0007229 9.72 DST ITGA6 ITGB4
6 keratinization GO:0031424 9.72 DSG1 DSG3 DSP EVPL PPL
7 extracellular matrix disassembly GO:0022617 9.69 LAMA3 LAMB3 LAMC2
8 cornification GO:0070268 9.65 DSG1 DSG3 DSP EVPL PPL
9 skin development GO:0043588 9.61 DSP ITGA6 ITGB4
10 intermediate filament cytoskeleton organization GO:0045104 9.57 DSP DST
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.54 HLA-DQB1 HLA-DRB1
12 amelogenesis GO:0097186 9.49 ITGA6 ITGB4
13 nail development GO:0035878 9.48 ITGA6 ITGB4
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.46 HLA-DQB1 HLA-DRB1
15 epidermis development GO:0008544 9.43 COL17A1 DSP EVPL LAMA3 LAMB3 LAMC2
16 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.4 HLA-DQB1 HLA-DRB1
17 hemidesmosome assembly GO:0031581 9.17 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.62 EVPL ITGA6 PLEC PPL
2 insulin-like growth factor I binding GO:0031994 9.26 ITGA6 ITGB4
3 structural molecule activity GO:0005198 9.26 DSP EVPL LAMA3 LAMB3
4 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
5 neuregulin binding GO:0038132 8.62 ITGA6 ITGB4

Sources for Bullous Pemphigoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....